Please login to the form below

Not currently logged in
Email:
Password:

GSK launches first-in-class epilepsy drug

GSK introduces Trobalt for the adjunct treatment of adults with partial-onset seizures

GlaxoSmithKline (GSK) has launched Trobalt (retigabine), the first in a new class of anti-epileptic drug (AED), for the adjunct treatment of adults with partial-onset seizures, and demonstrated significant effects in a treatment resistant patient population.

Retigabine is the first AED to target neuronal potassium channels, which are involved in inhibitory mechanisms in the brain. Inhibitory mechanisms are thought to have a role in seizure control.

Professor Martin J Brodie, director of the epilepsy unit at Western Infirmary, Glasgow, UK, said: "Trobalt represents a positive addition to the therapeutic armamentarium for the many adult patients with inadequately-controlled focal onset seizures."

The efficacy and safety of retigabine was established in two pivotal multicentre, randomised, double-blind, placebo-controlled, fixed dose studies where patients who were treatment resistant were recruited. Retigabine significantly improved seizure control, with a greater number of patients achieving a reduction in the number of seizures by 50 per or more, compared with placebo.

Retigabine, referred to as ezogabine in the US, is being jointly developed by GSK and Valeant.

17th May 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
How a design mindset can lead to better medical outcomes
By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...

Infographics